Antivirals for the treatment of mild and moderate COVID-19 in South Africa
DOI:
https://doi.org/10.7196/SAMJ.2023.v113i12.1066Keywords:
COVID-19, SARS-CoV-2, Antiviral, Test-and-treatAbstract
While the majority of COVID‐19 cases in South Africa (SA) are mild, patients with severe COVID‐19 requiring hospitalisation present with significant morbidity and mortality and place a substantial burden on healthcare services. Given the low vaccine uptake in SA and other low‐ and middle‐income countries in sub‐Saharan Africa, the high prevalence of comorbidities and limited healthcare system capacity, evidence‐based interventions that reduce the risk of severe disease and death should be considered for implementation. Several antiviral classes have been newly developed or repurposed to treat COVID‐19 early after infection to retard progression to severe disease and reduce the risk of death, particularly in the elderly and/or in patients with comorbidities. COVID‐19 antivirals such as remdesivir, nirmatrelvir/ ritonavir and molnupiravir are safe and cost‐effective and have received either full approval or emergency use authorisation from regulators. Using a proposed test‐and‐treat strategy, judicious use of antivirals could be impactful.
References
World Health Organization. WHO Coronavirus Dashboard. Geneva: WHO, 2023. https://covid10. who.int2023 (accessed 31 March 2023).
Kong JD, Tekwa EW, Gignoux‐Wolfsohn SA. Social, economic, and environmental factors influencing the basic reproduction number of COVID‐19 across countries. PLoS ONE 2021;16(6):e0252373. https://doi.org/10.1371/journal.pone.0252373
World Health Organization. WHO coronavirus dashboard table view situation by region, country, territory and area. Geneva: WHO, 2023.
World Health Organization. WHO Coronavirus Dashboard. Geneva: WHO, 2022. https://covid19. who.int/ (accessed 20 November 2022).
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID‐19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Centers for Disease Control and Prevention. JAMA 2020;323(13):1239‐1242. https://doi.org/10.1001/jama.2020.2648
Esper FP, Adhikari TM, Tu ZJ, et al. Alpha to Omicron: Disease severity and clinical outcomes of major SARS‐CoV‐2 variants. J Infect Dis 2023;227(3):344‐352. https://doi.org/10.1093/infdis/jiac411
Jassat W, Karim SSA, Mudara C, et al. Clinical severity of COVID‐19 in patients admitted to hospital during the omicron wave in South Africa: A retrospective observational study. Lancet Glob Health 2022;10(7):e961‐e969. https://doi.org/10.1016/S2214‐109X(22)00114‐0
Madhi SA, Nel J. Epidemiology of severe COVID‐19 from South Africa. Lancet HIV 2021;8(9):e524‐e526. https://doi.org/10.1016/S2352‐3018(21)00183‐1.
Cabore JW, Karamagi HC, Kipruto HK, et al. COVID‐19 in the 47 countries of the WHO African region: A modelling analysis of past trends and future patterns. Lancet Glob Health 2022;10(8):e1099‐e1114. https://doi.org/10.1016/S2214‐109X(22)00233‐9
Vassall A, Sweeney S, Kahn J, et al. Reference case for estimating the costs of global health services and interventions. Global Health Cost Consortium, 2017. https://ghcosting.org/pages/standards/ reference_case (accessed 15 May 2023).
Edoka I, Fraser H, Jamieson L, Meyer‐Rath G, Mdewa W. Inpatient care costs of COVID‐19 in South Africa’s public healthcare system. Int J Health Policy Manage 2022;11(8):1354‐1361. https://doi. org/10.34172/ijhpm.2021.24
Our World in Data. Number of COVID‐19 patients in hospital. Our World in Data, 2022. https:// ourworldindata.org/grapher/current‐covid‐patients‐hospital?tab=table&country=~ZAF (accessed 11 October 2022).
Our World in Data. Current number of COVID‐19 Patients in ICU. Our World in Data, 2022. https:// ourworldindata.org/grapher/current‐covid‐patients‐icu?tab=table (accessed 11 October 2022).
National Institiute for Communicable Diseases. Daily Hospital Surveillance (DATCOV) Report. Pretoria: NICD, 2022.
Pereznieto P, Oehler I. Social costs of the COVID‐19 pandemic 2021. https://theindependentpanel. org/wp‐content/uploads/2021/05/Background‐paper‐9‐Social‐impact.pdf (accessed 15 May 2023). 16. Saladino V, Algeri D, Auriemma V. The psychological and social impact of COVID‐19: New
perspectives of well‐being. Front Psychol 2020;11:577684.
Madhi SA. Why it is time for the national coronavirus command council to go. Business Live, 2023.
https://www.businesslive.co.za/bd/opinion/2022‐02‐03‐shabir‐a‐madhi‐why‐it‐is‐time‐for‐the‐
national‐coronavirus‐command‐council‐to‐go/ (accessed 15 May 2023).
Lancet. Access to COVID‐19 vaccines: Looking beyond COVAX. Lancet 2021;397(10278):941. https://
doi.org/10.1016/S0140‐6736(21)00617‐6
COVID‐19 vaccine may be less effective in some people with cancer. Cancer, 2021. https://www.cancer.
gov/news‐events/cancer‐currents‐blog/2021/covid‐vaccine‐limited‐protection‐in‐cancer‐patients
(accessed 18 May 2023).
Boyer B, Chupp E, Edson G, et al. Pills to people: Accelerating equitable global access to oral
therapeutics for COVID‐19. Covid Gap, 2022. https://covid19gap.org/insights/pills‐to‐people‐
accelerating‐equitable‐global‐access‐to‐oral‐therapeutics‐for‐covid‐19 (accessed 18 May 2023).
Cooper S, van Rooyen H, Wiysonge CS. COVID‐19 vaccine hesitancy in South Africa: How can we maximise uptake of COVID‐19 vaccines? Expert Rev Vacc 2021;20(8):921‐933. https://doi.org/10.10
/14760584.2021.1949291
World Health Organization. COVID‐19 vaccination roll‐out stagnates in Africa 2022. Geneva: WHO, 2022. https://www.afro.who.int/news/covid‐19‐vaccination‐roll‐out‐stagnates‐africa (accessed 25 May 2023).
Biotechnology Innovation Organisation. BIO COVID‐19 Therapeutic Development Tracker. New York: BIO, 2022.
World Health Organization. License agreements for COVID‐19 therapeutics. Geneva: WHO, 2022. 25. Shadlen KC. Accelerating pooled licensing of medicines to enhance global production and equitable
access. Lancet 2022;400(10352):632‐634. https://doi.org/10.1016/S0140‐6736(22)01013‐3
Xie Y, Choi T, Al‐Aly Z. Association of treatment with nirmatrelvir and the risk of post‐COVID‐19
condition. JAMA Intern Med 2023;183(6):554‐564. https://doi.org/10.1001/jamainternmed.2023.0743 27. World Health Organization. Primary health care systems: Case study from South Africa. Geneva:
WHO, 2017.
Pfizer. Fact sheet for healthcare providers: Emergency use authorisation for Paxlovid. New York: Pfizer, 2022.
Pfizer. Fact sheet for patients, parents, and caregivers: Emergency user authorisation (EUA) of Paxlovid for coronavirus disease 2019 (COVID‐19). New York: Pfizer, 2022.
Pfizer. Pfizer receives US FDA emergency use authorisation for novel COVID‐19 oral antiviral treatment. New York: Pfizer, 2021. https://www.pfizer.com/news/press‐release/press‐release‐detail/ pfizer‐receives‐us‐fda‐emergency‐use‐authorisation‐novel (accessed 23 May 2023).
European Medicines Agency. EMA issues advice on use of Lagevrio (molnupiravir) for the treatment of COVID‐19 2021. https://www.ema.europa.eu/en/news/ema‐issues‐advice‐use‐lagevrio‐molnupiravir‐ treatment‐covid‐19 (accessed 20 May 2023).
Food and Drug Administration. Lagevrio (Molnupiravir) HCP FS 02012023. FDA, 2021.
Hammond J, Leister‐Tebbe H, Gardner A, et al. Oral nirmatrelvir for high‐risk, nonhospitalised adults
with COVID‐19. N Engl J Med 2022;386(15):1397‐1408. https://doi.org/10.1056/NEJMoa2118542
Merck. Merck and Ridgeback Biotherapeutics provide update on results from MOVE‐OUT study of molnupiravir, an investigational oral antiviral medicine, in at risk adults with mild‐to‐moderate COVID‐19. Merck, 2021. https://www.merck.com/news/merck‐and‐ridgeback‐biotherapeutics‐ provide‐update‐on‐results‐from‐move‐out‐study‐of‐molnupiravir‐an‐investigational‐oral‐antiviral‐
medicine‐in‐at‐risk‐adults‐with‐mild‐to‐moderate‐covid‐19/ (accessed 25 May 2023).
Burdet C, Ader F. Real‐world effectiveness of oral antivirals for COVID‐19. Lancet
;400(10359):1175‐1176. https://doi.org/10.1093/infdis/jiad324
Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real‐world effectiveness of
molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in‐hospital outcomes among community‐dwelling, ambulatory patients with confirmed SARS‐CoV‐2 infection during the omicron wave in Hong Kong: An observational study. Lancet 2022;400(10359):1213‐1222. https://doi.org/10.1016/S0140‐6736(22)01586‐0
Saravolatz LD, Depcinski S, Sharma M. Molnupiravir and nirmatrelvir‐ritonavir: Oral coronavirus disease 2019 antiviral drugs. Clin Infect Dis 2022;76(1):165‐171. https://doi.org10.1093/cid/ciac180
Lewnard JA, McLaughlin JM, Malden D, et al. Effectiveness of nirmatrelvir‐ritonavir against hospital admission or death: A cohort study in a large US healthcare system. medRxiv 2023:2022.10.02.22280623
Butler CC, Hobbs FDR, Gbinigie OA, et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID‐19 at increased risk of adverse outcomes (PANORAMIC): An open‐label, platform‐adaptive randomised controlled trial. Lancet 2023;401(10373):281‐293. https://
doi.org10.1016/S0140‐6736(22)02597‐1
Yip TC, Lui GC, Lai MS, et al. Impact of the use of oral antiviral agents on the risk of hospitalisation in community coronavirus disease 2019 patients (COVID‐19). Clin Infect Dis 2023;76(3):e26‐e33. https://doi.org10.1093/cid/ciac687
Ebell MH. Nirmatrelvir/ritonavir reduces hospitalisation, mortality in patients 65 years and older with COVID‐19; effect on younger patients unclear. Am Fam Physician 2023;107(3):316.
Cheema HA, Jafar U, Sohail A, et al. Nirmatrelvir‐ritonavir for the treatment of COVID‐19 patients: A systematic review and meta‐analysis. J Med Virol 2023;95(2):e28471. https://doi.org10.1002/ jmv.28471
Reis S, Metzendorf MI, Kuehn R, et al. Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19. Cochrane Database Syst Rev 2022;9(9):Cd015395. https://doi.org/10.1002/14651858. cd015395.pub2
Arbel R, Wolff Sagy Y, Hoshen M, et al. Nirmatrelvir use and severe covid‐19 outcomes during the omicron surge. N Engl J Med 2022;387(9):790‐798. https://doi.org/10.1056/nejmoa2204919
Sanderson T, Hisner R, Donovan‐Banfield I, Peacock T, Ruis C. Identification of a molnupiravir‐associated mutational signature in SARS‐CoV‐2 sequencing databases. medRxiv 2023:2023.01.26.23284998. https:// doi.org10.1056/NEJMoa2204919
National Institute for Communicable Diseases. SARS‐COV‐2 genomic surveillance update. Johannesburg: NICD, 2023.
Gonzales TL, Skarda P, Bird TG, et al. LB1530. Clinical benefit of oral sabisabulin for hospitalised adults with COVID‐19 on supplemental oxygen. Open Forum Infect Dis 2022;9(Suppl2):ofac492.1876 https://doi.org10.1093/ofid/ofac492.1876
Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID‐19 (COV‐BARRIER): A randomised, double‐blind, parallel‐group, placebo‐controlled phase 3 trial. Lancet Respir Med 2021;9(12):1407‐1418. https://doi.org10.1016/ S2213‐2600(21)00331‐3
McCarthy MW. Ensitrelvir as a potential treatment for COVID‐19. Expert Opin Pharmacother 2022;23(18):1995‐1998. https://doi.org10.1080/14656566.2022.2146493
Cao Z, Gao W, Bao H, et al. VV116 versus nirmatrelvir‐ritonavir for oral treatment of COVID‐19. N Engl J Med 2023;388(5):406‐417. https://doi.org10.1056/NEJMoa2208822
World Health Organization. Access to COVID‐19 tools accelerator strategic plan and budget. Geneva: WHO, 2022.
European Medicines Agency. EMA reviewing data on sabisabulin for COVID‐19. EMA, 2022. https:// www.ema.europa.eu/en/news/ema‐reviewing‐data‐sabisabulin‐covid‐19 (accessed 25 May 2023).
Gilead Sciences. Highlights of prescribing information: Veklury, 2022. https://www.gilead.com/‐/
media/files/pdfs/medicines/covid‐19/veklury/veklury_pi.pdf (accessed 20 May 2023).
Verupharma. Biopharmaceutical company focused on COVID‐19 and oncology. Very Corporate, 2022. https://verupharma.com/wp‐content/uploads/2022/05/Veru‐Corporate‐Presentation‐May‐2022.pdf
(accessed 25 May 2023).
Barnette KG, Gordon MS, Rodriguez D, et al. Oral sabizabulin for high‐risk, hospitalised adults
with COVID‐19: Interim analysis. N Engl J Med Evidence 2022;1(9):220145. https://doi.org10.1056/
EVIDoa2200145
Hauteng Pharma. Ensitrelvir, an oral antiviral drug for COVID‐19 treatment. Hauteng Pharma, 2022. https://www.molecularcloud.org/p/ensitrelvir‐an‐oral‐antiviral‐drug‐for‐covid‐19‐treatment (accessed 23 May 2023).
Mukaea H, Yotsuyanagi H, Ohmagaric N, et al. A randomised phase 2/3 study of ensitrelvir, a novel oral SARS‐CoV‐2 3C‐like protease 3 inhibitor, in Japanese patients with mild‐to‐moderate COVID‐19 or asymptomatic SARS‐CoV‐2 infection: Results of the phase 2a part. Antimicrob Agents Chemother 2022;66(10):e0069722. https://doi.org10.1128/aac.00697‐222022
The COVID Treatment Quick Start Consortium. Duke University, 2022. https://www. covidcollaborative.us/initiatives/quickstart‐consortium#:~:text=What%20is%20COVID%20 Treatment%20Quick,Hilton%20Foundation (accessed 25 May 2023).
Quick Start Consortium. Zambia Becomes First Country to Receive PAXLOVID through COVID Treatment Quick Start Consortium. Quick Start Consortium, 2022. https://dukeghic.org/wp‐content/ uploads/sites/20/2022/12/Paxlovid_PR_22‐Dec‐2022_Zambia.pdf (accessed 23 May 2023).
National Institutes of Health. Coronavirus disease 2019 (COVID‐19) treatment guidelines. New York: NIH, 2022.
World Health Organization. Therapeutics and COVID‐19: Living guidelines. Geneva: WHO, 2022. 62. Girum T, Yasin F, Wasie A, Shumbej T, Bekele F, Zeleke B. The effect of ‘universal test and treat’ program on HIV treatment outcomes and patient survival among a cohort of adults taking antiretroviral treatment (ART) in low income settings of Gurage zone, South Ethiopia. AIDS Research and Therapy
;17(1):19. https://doi.org10.1186/s12981‐020‐00274‐3
Havlir D, Lockman S, Ayles H, Larmarange J, Chamie G, Gaolathe T, et al. What do the Universal Test
and Treat trials tell us about the path to HIV epidemic control? J Int AIDS Soc 2020;23(2):e25455.
https://doi.org10.1002/jia2.25455
Han AX, Hannay E, Carmona S, et al. Estimating the potential need and impact of SARS‐CoV‐2 test‐and‐treat programs with oral antivirals in low‐and‐middle‐income countries. medRxiv 2022;13:2022.10.05.22280727. https://doi.org10.1101/2022.10.05.22280727
Brault A, Tran‐Kiem C, Couteaux C, et al. Modelling the end of a Zero‐COVID strategy using nirmatrelvir/ritonavir, vaccination and NPIs in Wallis and Futuna. Lancet Reg Health West Pac 2023;30:100634. https://doi.org10.1016/j.lanwpc.2022.100634
Schiffer JT, Johnston C, Wald A, Corey L. An early test‐and‐treat strategy for severe acute respiratory syndrome coronavirus 2. Open For Infect Dis 2020(7):ofaa232. https://doi.org/10.1093/ofid/ofaa232
South African Health Products Regulatory Authority. SAHPRA approves antigen self‐test kits for public use. Cape Town: SAHPRA, 2022.
Mantzourani E, Cannings‐John R, Evans A, Ahmed H. To swab or not to swab? Using point‐of‐care tests to detect Group A Streptococcus infections as part of a Sore Throat Test and Treat service in community pharmacy. J Antimicrobial Chemo 2022;77(3):803‐806. https://doi.org/10.1093/jac/dkab470
Smith DJ, McGill L, Carranza D, Adeyemo A, Hakim AJ. Global engagement of pharmacists in test and treat initiatives: Bringing care from clinics to communities. J Am Pharm Assoc 2023;63(1):419‐423. https://doi.org/10.1016/j.japh.2022.10.013
Gentles A. COVID‐19 test‐and‐treat strategy: A precedent‐setting opportunity for us as societal leaders. J Am Pharmacists Assoc 2023;63(1):416‐418. https://doi.org/10.1016/j.japh.2022.11.008
Wroe EB, Seung KJ, Baker BK, Farmer PE. Test and treat: A missing link in the global fight against
COVID‐19. Lancet Glob Health 2022;10(2):e181‐e182. https://doi.org/10.1016/S2214‐109X(21)00568‐4 72. Gherghescu I, Delgado‐Charro MB. The biosimilar landscape: An overview of regulatory approvals by the EMA and FDA. Pharmaceutics 2020;13(1):48. https://doi.org/10.3390/pharmaceutics13010048 73. Pepperrell T, Ellis L, Wang J, Hill A. Barriers to worldwide access for Paxlovid, a new treatment for
COVID‐19. Open For Infect Dis 2022;9(9):ofac174. https://doi.org/10.1093/ofid/ofac174
Bright B, Babalola CP, Sam‐Agudu NA, et al. COVID‐19 preparedness: Capacity to manufacture vaccines, therapeutics and diagnostics in sub‐Saharan Africa. Globalis Health 2021;17(1):24. https://
doi.org/10.1186/s12992‐021‐00668‐6
Hengel B, Causer L, Matthews S, et al. A decentralised point‐of‐care testing model to address inequities in the COVID‐19 response. Lancet Infect Dis 2021;21(7):e183‐e190. https://doi.org/10.1016/S1473‐ 3099(20)30859‐8
World Health Organization. European Union Funding boosts COVID‐19 vaccination in Africa. Geneva: WHO, 2022. https://www.afro.who.int/news/european‐union‐funding‐boosts‐covid‐19‐ vaccination‐africa (accessed 20 May 2023).
Chou W‐YS, Budenz A. Considering emotion in COVID‐19 vaccine Communication: Addressing vaccine hesitancy and fostering vaccine confidence. Health Comm 2020;35(14):1718‐1722. https://doi. org/10.1080/10410236.2020.1838096
COVID‐19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID‐19) Treatment Guidelines. Bethesda: National Institutes for Health, 2022. https://www.covid19treatmentguidelines.nih.gov/ (accessed 23 May 2023).
World Health Organization. Six in seven COVID‐19 infections go undetected in Africa. Geneva: WHO, 2021. https://www.afro.who.int/news/six‐seven‐covid‐19‐infections‐go‐undetected‐africa (accessed 25 May 2023)
Torres I, Sippy R, Sacoto F. Assessing critical gaps in COVID‐19 testing capacity: The case of delayed results in Ecuador. BMC Pub Health 2021;21(1):637. https://doi.org/10.1186/s12889‐021‐10715‐x.
Tsiouris F, Hartsough K, Poimboeuf M, et al. Rapid scale‐up of COVID‐19 training for frontline health
workers in 11 African countries. Hum Res Health 2022;20(1):43. https://doi.org/10.1186/s12960‐022‐
‐8.
Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe COVID‐19 in outpatients. N Engl J Med 2022;386(4):305‐315. https://doi.org/10.1056/NEJMoa2116846.
Bhimraj A, Morgan RL, Shumaker AH, et al. IDSA guidelines on the treatment and management of patients with COVID‐19. Clin Infect Dis. 2020;27:ciaa478. https://doi.org/10.1093/cid/ciaa478.
Seytre B, Barros C, Bona P, et al. Revisiting COVID‐19 communication in Western Africa: A health literacy‐based approach to health communication. Am J Trop Med Hyg 2021;105(3):708‐712. https:// doi.org/10.4269/ajtmh.21‐0013.
Van Vuuren CJJ, van Vuuren JMJ. Perspectives of healthcare workers in South Africa on COVID‐19 vaccination passports. Health SA 2022;27:1823. https://doi.org/10.4102/hsag.v27i0.1823.
Medicines Patent Pool. Medicines patent pool progress and achievements: Licences. MPP, 2023. https://medicinespatentpool.org/who‐we‐are/about‐us (accessed 25 May 2023).
Statistics South Africa. Mid‐Year Population Estimates: 2021 (P0302). Pretoria: Stats SA, 2021.
Joint United Nations Programme on HIV and AIDS. South Africa. Country Factsheet. Geneva: UNAIDS,
https://www.unaids.org/en/regionscountries/countries/southafrica (accessed 25 May 2023).
Downloads
Published
License
Copyright (c) 2023 R Perumal, V Naidoo, S Govender, T N Gengiah
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.
